Abstract: Bunting (100) having core bottom (110) extending over top of the child carrier seat (11/21) and shorter, core top (130) for enclosing child, along with like-sized, optional, decorative/functional cover (140), forming three, connectable, main layers (FIG. 6) or, alternatively, with the cover directly connected to core bottom, using compatible side fastener, zipper sets. The bunting bottom end is open allowing child's feet to extend down out from bunting bottom. Bunting-to-stroller, side attachments use special bunting/suspender clips (150; FIG. 14). Child's feet alternatively placed in integral boot pouch (120) attached to core bottom's bottom and flipped-over moveable between back and front sides (cf. FIGS. 1 & 2) and, alternatively, usable as storage pouch for rolled up, integral bunting (FIGS. 15 & 16). Core bottom's top can be cinched up forwardly to form hood or backwardly for attachment around stroller seat's top.

Abstract: There is disclosed anti-receptor and growth blocking agents to the vitamin B12/transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the vitamin B12/transcobalamin II receptor or binding sites, causing cellular depletion of vitamin B12, thus inhibiting cell division or causing apoptosis. Anti-receptor and growth blocking agents of the present invention include proteins (such as antibodies and antibody derivatives), peptides and small organic molecules. In a preferred embodiment, the anti-receptor agent is an antibody to the vitamin B12/transcobalamin II receptor.

Abstract: Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.